Key Highlights

  • Shares rose 6.34% in today's session to around $41.74, touching a new 52-week high.
  • The FDA approved Weltruza, a once-monthly subcutaneous injectable form of olanzapine for adults with schizophrenia.
  • The drug requires no loading doses, no oral supplementation, and no post-injection monitoring, addressing a key treatment gap.
  • Several research firms raised their price targets on the stock following the approval.

First Once-Monthly Subcutaneous Olanzapine Wins Approval

Teva Pharmaceutical (NYSE:TEVA) shares jumped in today's session after the FDA approved Weltruza, a new once-monthly injectable form of olanzapine for the treatment of schizophrenia in adults. The approval adds a long-acting option to Teva's neuroscience portfolio, which already includes several other branded treatments.

Teva is a global pharmaceutical company built around a large generics Business alongside a growing portfolio of innovative medicines. Olanzapine has been a widely prescribed daily oral treatment for schizophrenia for decades, but adherence to daily medication has remained a persistent challenge for many patients.

No Loading Doses or Post-Injection Monitoring Required

What sets Weltruza apart from an earlier intramuscular long-acting olanzapine option is that it is injected under the skin rather than into muscle, and it does not require a loading dose or a period of monitoring immediately after injection, which has been a common barrier to broader use of long-acting antipsychotics.

Clinical trial results supporting the approval showed overall improvement in symptoms, a meaningful reduction in illness severity, and better personal and social functioning, with a safety profile consistent with oral olanzapine.

Analyst Targets Move Higher as Shares Hit New Highs

Teva carries a market Capitalization near $48.6 billion. Following the approval, several research firms raised their price targets on the stock, and shares touched a new 52-week high during today's session, trading well above trailing averages on Volume well above normal levels.

Outlook: U.S. Launch and Earnings Are the Next Milestones

With the drug expected to become available in the U.S. within the coming weeks, investors will likely watch early uptake trends alongside the company's upcoming third-quarter earnings report for further detail on how Weltruza fits into Teva's broader growth strategy.